FOXO TECHNOLOGIES (FOXO) Company Report

FOXO Technologies Inc. entered into a Series E Preferred Stock Exchange Agreement with Rennova Health, Inc., effective December 31, 2025, to settle $200,000 in prior advances.
In exchange for the prior advances, FOXO Technologies will issue 8,000 shares of Series E Cumulative Redeemable Secured Preferred Stock to Rennova, with a stated value of $25.00 per share.
This transaction is a related party transaction because Seamus Lagan, the Chief Executive Officer of FOXO Technologies, also controls Rennova Health, Inc..
The Board of Directors of FOXO Technologies approved the transaction, with conflicted directors abstaining, determining it was fair and in the best interests of the Company and its unaffiliated stockholders.

6 hours ago

FOXO Technologies Inc. Subsidiary Expands Clinical Capabilities and Increases Authorized Shares

FOXO

New Projects/Investments

FOXO Technologies Inc.'s subsidiary, Big South Fork Medical Center, expanded its clinical capabilities by adding inpatient tele-specialty services and cardiac diagnostics.
The expansion includes tele-specialty coverage in cardiology, pulmonology, and nephrology, and on-site echocardiography services with professional interpretation from CompuMed.
This initiative is expected to increase net revenues and improve care access for the hospital.
FOXO Technologies Inc. also increased its authorized shares of Common Stock from 2,500,000,000 to 10,000,000,000 shares, effective January 18, 2026.

Jan 20, 2026, 10:10 PM

FOXO Technologies Amends Preferred Stock Terms and Increases Authorized Shares

FOXO

Convertible Preferred Issuance

Proxy Vote Outcomes

FOXO Technologies Inc. filed amendments to its Certificate of Incorporation on December 16, 2025, for Series B and Series C Cumulative Convertible Redeemable Preferred Stock, which revise the conversion price and remove the mandatory conversion provision.
On December 16, 2025, the majority stockholder, Rennova Health, Inc. (holding 98.6% of voting rights), approved an amendment to increase authorized Class A Common Stock from 2,500,000,000 to 10,000,000,000 shares and Preferred Stock from 10,000,000 to 20,000,000 shares.
The majority stockholder also approved the re-election of five directors to the Board and ratified Kreit & Chiu CPA LLP as the independent auditor for fiscal year 2025.
As of the document date, 3,245 shares of Series B Preferred Stock are issued and outstanding , with a stated value of $1,000.00 per share and cumulative cash dividends payable quarterly starting March 15, 2025.

Dec 19, 2025, 10:20 PM

FOXO Technologies Completes Acquisition of Vector Biosource Inc.

FOXO

M&A

Convertible Preferred Issuance

FOXO Technologies Inc. completed the acquisition of Vector Biosource Inc. on September 19, 2025, following a Stock Purchase Agreement entered into on September 9, 2025.
The initial purchase price included $500,000 in cash, 60,000 shares of Series E Cumulative Redeemable Secured Preferred Stock ($1.5 million stated value), and warrants to purchase up to $2 million of the Company's common stock.
An additional up to 80,000 shares of Series E Preferred Stock (up to $2.0 million in stated value) are contingent on future revenue and cash collection milestones, and FOXO will fund up to $1.2 million for Vector's growth initiatives.
Vector Biosource Inc. reported net revenues of approximately $225,000 for Q2 2025.
The Series E Preferred Stock and warrants were issued as unregistered sales of equity securities, relying on exemptions from registration requirements.

Sep 22, 2025, 9:20 PM

FOXO Technologies Inc. to acquire Vector BioSource Inc.

FOXO

M&A

New Projects/Investments

Convertible Preferred Issuance

FOXO Technologies Inc. entered into a Stock Purchase Agreement (SPA) on September 9, 2025, to acquire Vector BioSource Inc..
The consideration for the acquisition includes $500,000 in cash, 60,000 shares of Series E Cumulative Redeemable Secured Preferred Stock, and three-year warrants to purchase up to $2,000,000 of Class A Common Stock.
An additional 80,000 shares of Series E Preferred Stock are contingent on Vector BioSource Inc. achieving at least $4,000,000 in Qualifying Revenue during the 12-month period between the first and second anniversary of the closing.
The closing of the SPA is subject to conditions, including completion of due diligence, finalization of warrant terms and employment agreements, and funding of up to $1.2 million for Vector's cash requirements.

Sep 15, 2025, 9:30 PM

FOXO Technologies Inc. Announces Agreement to Acquire Vector Biosource Inc.

FOXO

M&A

New Projects/Investments

Convertible Preferred Issuance

FOXO Technologies Inc. announced on September 11, 2025, that it has signed a stock purchase agreement to acquire Vector Biosource Inc., a provider of information, data, and biospecimen sourcing for the biotechnology, clinical research, and pharmaceutical research industries.
Vector Biosource Inc. generated net revenues of approximately $225,000 in Q2 2025 and is expected to grow significantly post-acquisition.
The expected purchase price includes $500,000 in cash, 60,000 shares of Series E Cumulative Redeemable Secured Preferred Stock ($1.5 million in stated value), and warrants to purchase $2 million of common stock.
Up to an additional 80,000 shares of Series E Preferred Stock (up to $2.0 million in stated value) are contingent on Vector achieving certain revenue and cash collection milestones.
FOXO has also agreed to fund up to $1.2 million for Vector's growth initiatives.